ADAMTS16 and ovarian cancer: To fill in this knowledge gap, we systematically carried out multiple in vitro and in vivo experimental assays and demonstrated that the introduction of ADAMTS16 mutants into ovarian cancer cells resulted in both improved sensitivity to cisplatin treatment and reduced cell migration and invasion, providing experimental evidence to support the genomic observation in a large population of patient cohort.